Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simonetta Chiara Stani

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
Antiangiogenic agentsSimonetta Chiara Stani, Barbara Capaccetti, Paola Bonginelli, et al.
American Journal of Clinical Oncology|June 11, 2003
Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC)Daniela De Candis, Simonetta Chiara Stani, Paolo Bidoli, et al.
Cancer Journal (Sudbury, Mass.)|August 2, 2005
The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlatesGiampietro Gasparini, Sabrina Meo, Giuseppe Comella, et al.
Breast Cancer Research and Treatment|November 30, 2004
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancerAlessandro Morabito, Domenico Gattuso, Simonetta Chiara Stani, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
Antiangiogenic agentsSimonetta Chiara Stani, Barbara Capaccetti, Paola Bonginelli, et al.
American Journal of Clinical Oncology|June 11, 2003
Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC)Daniela De Candis, Simonetta Chiara Stani, Paolo Bidoli, et al.
Cancer Journal (Sudbury, Mass.)|August 2, 2005
The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlatesGiampietro Gasparini, Sabrina Meo, Giuseppe Comella, et al.
Breast Cancer Research and Treatment|November 30, 2004
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancerAlessandro Morabito, Domenico Gattuso, Simonetta Chiara Stani, et al.
Pageof 1